Stockreport

IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results

Insight Molecular Diagnostics Inc.  (IMDX) 
PDF Submitted GraftAssureDx™ for kidney transplant rejection testing for FDA review on Wednesday, March 25Welcomed second favorable head-to-head data set from an independent [Read more]